Difluoromescaline (DFM), also known as 4-difluoromethoxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is a difluorinated derivative of mescaline.
The drug's dose range is 50 to 100mg orally and its duration is 12 to 18hours. It is about 3- or 4-fold more potent than mescaline and has a longer duration in comparison. The drug is said to produce strong psychedelic effects.
Difluoromescaline interacts with serotonin receptors and acts as a low-potency full agonist of the serotonin 5-HT2A receptor.
It was first described in the scientific literature by Daniel Trachsel in 2012. The drug's pharmacology was studied in more detail in 2021. It is not a controlled substance in Canada as of 2025.
See also Scaline Metadifluoromescaline Trifluoromescaline Difluoroescaline Trifluoroescaline Fluoroescaline Fluoroproscaline Trifluoroproscaline 3C-DFM
References
External links Difluoromescaline - Isomer Design